From Pre-clinical to Human—Prediction of Oral Absorption and Drug-drug Interaction Potential Using Physiologically-based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example Publication From Pre-clinical to Human—Prediction of Oral Absorption and Drug-drug Interaction Potential Using Physiologically-based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example A case example is presented in which the physiologically based modeling approach has been used…Danielle Pillsbury2012年3月1日
Use of a Multistaged Time-dependent Inhibition Assay to Assess the Impact of Intestinal Metabolism on Drug-drug Interaction Potential Publication Use of a Multistaged Time-dependent Inhibition Assay to Assess the Impact of Intestinal Metabolism on Drug-drug Interaction Potential In early discovery, compounds are often eliminated because of their potential to undergo metabolic activation…Danielle Pillsbury2012年3月1日
Physiologically-based PharmacoKinetic (PBPK) Modeling Tools: How to Fit with Our Needs? 論文 Physiologically-based PharmacoKinetic (PBPK) Modeling Tools: How to Fit with Our Needs? In 2005, a survey compared a number of commercial PBPK software available at the time,…Danielle Pillsbury2012年3月1日
Application of IVIVE and PBPK Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies Publication Application of IVIVE and PBPK Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies Prospective simulations of human pharmacokinetic (PK) parameters and plasma concentration-time curves using in vitro in…Danielle Pillsbury2012年3月1日
Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events Publication Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events Positive allosteric modulators ('potentiators') of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) have been shown to display…Danielle Pillsbury2012年3月1日
Evaluation of Methods for Achieving Stable INR in Healthy Subjects During a Multiple-dose Warfarin Study Publication Evaluation of Methods for Achieving Stable INR in Healthy Subjects During a Multiple-dose Warfarin Study No consistent method is available for finding stable warfarin maintenance doses and fast stabilization of…Danielle Pillsbury2012年3月1日
Mechanism-based Population Modeling of the Effects of Vildagliptin on GLP-1, Glucose, and Insulin in Patients with Type 2 Diabetes Publication Mechanism-based Population Modeling of the Effects of Vildagliptin on GLP-1, Glucose, and Insulin in Patients with Type 2 Diabetes The aim of this study was to build a mechanism-based population pharmacodynamic model to describe…Danielle Pillsbury2012年3月1日
Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites Publication Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites The purpose of this analysis was to develop a population pharmacokinetic model for CS-917, an…Danielle Pillsbury2012年3月1日
Physiologically-based Pharmacokinetic (PBPK) Modeling: It is Here to Stay! 論文 生理学的薬物動態 (PBPK) モデリング&シミュレーション:It is Here to Stay! Physiologically based pharmacokinetic (PBPK) modeling is an extremely useful approach with the ability to predict…Danielle Pillsbury2012年3月1日
Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-ritonavir and Fosamprenavir-ritonavir Publication Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-ritonavir and Fosamprenavir-ritonavir This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence…Danielle Pillsbury2012年2月1日